Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 16,133 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
Interventions: Biospecimen Collection, Genotyping, Survey Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Psoriasis
Interventions: DFD01 Spray, Vehicle Spray; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Mobile, Alabama • Tempe, Arizona • Oceanside, California + 24 more

Conditions: Foot Ulcer, Diabetic
Interventions: NuShield, Affinity, Standard of Care; Other
Lead sponsor: NuTech Medical, Inc; Industry
Eligibility: 19 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Fresno, California • Indianapolis, Indiana • Opelousas, Louisiana + 4 more

Conditions: Breast Cancer
Interventions: Radiolabeled (99mTc) GP (Glycopeptide); Radiation
Lead sponsor: SeeCure LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound, Full Field Digital Mammography; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Skin Laxity, Lipodystrophy
Interventions: Rotational fractional resection (1.5mm diameter device); Device
Lead sponsor: Recros Medica, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Campbell, California • Newport Beach, California • Roseville, California + 3 more

Conditions: Herpes Labialis
Interventions: Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), Placebo cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years and older
Enrollment: 4,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more

Conditions: Breast Cancer
Interventions: Placebo, Lidocaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab; Drug
Lead sponsor: GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more

Conditions: Breast Cancer
Interventions: No intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: Breast Cancer
Interventions: Biopsy-Site Marker Placement.; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Breast Cancer
Interventions: STA-9090; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis
Interventions: R3R01; Drug
Lead sponsor: River 3 Renal Corp.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; Network
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: La Jolla, California • Seattle, Washington

Conditions: Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions: therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction; Biological · Procedure · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 58
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more

Conditions: Kinky Hair Syndrome
Interventions: Copper Histidine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatitis, Atopic
Interventions: Bathing Additive; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer, Solid Tumor, Cancer of Skin
Interventions: 2141 V-11; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Tumors, Breast
Interventions: DBT and FFDM; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Greenville, North Carolina • Sioux Falls, South Dakota

Conditions: Radiation Dermatitis
Interventions: StrataXRT, Calendula, Aquaphor; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

CONFORM: Rotational Fractional Resection for Submental Contouring

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery:

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)

A Study in Subjects With Moderate Atopic Dermatitis

Biopsy-site-marker in Breast Cancer

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Copper Histidine Therapy for Menkes Diseases

Bathing Additives in Pediatric Atopic Dermatitis

A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors